Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.35 |
| ▸ | TRHR | P34981 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8669058 | 0.82 | POLB (0.39) | POLBSMN1; SMN2MEN1KMT2AHDAC3 | |
| SCHEMBL2190498 | 0.82 | CNR1 (0.41) | POLBSMN1; SMN2MEN1KMT2AACACB | |
| SCHEMBL26508302 | 0.80 | ALDH1A1 (0.45) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL9719683 | 0.80 | ALDH1A1 (0.45) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL9719680 | 0.80 | ALDH1A1 (0.45) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL25834350 | 0.80 | HDAC3 (0.41) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL19875638 | 0.80 | ALDH1A1 (0.45) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL10359347 | 0.78 | TRHR (0.42) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL28864215 | 0.78 | TRHR (0.42) | POLBHDAC3HDAC1HDAC2HDAC10 | |
| SCHEMBL19359174 | 0.78 | TRHR (0.42) | POLBHDAC3HDAC1HDAC2HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0253882-A4 | ACYLATED CYANAMIDE COMPOSITION. | UNIV MINNESOTA (US) | 1990-06-27 | — | — | EP | claimed |
| US-4870056-A | DETERRENTS OF ALCOHOL ABUSE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1989-09-26 | — | — | US | claimed |
| EP-0253882-A1 | ACYLATED CYANAMIDE COMPOSITION | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1988-01-27 | — | — | EP | claimed |
| WO-1987004348-A1 | ACYLATED CYANAMIDE COMPOSITION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1987-07-30 | — | — | WO | claimed |
| US-9026372-B2 | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20110117050-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110097426-A1 | Methods for Safe and Effective Treatment Using Oxazaphosphorine Drugs | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110082115-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | US | disclosed |
| US-4940816-A | Acylated cyanamide compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0253882-A4 | ACYLATED CYANAMIDE COMPOSITION. | UNIV MINNESOTA (US) | 1990-06-27 | — | — | EP | disclosed |
| US-4870056-A | DETERRENTS OF ALCOHOL ABUSE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1989-09-26 | — | — | US | disclosed |
| US-4726941-A | Acylated cyanamide composition for treating ethanol ingestion | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1988-02-23 | — | — | US | disclosed |
| EP-0253882-A1 | ACYLATED CYANAMIDE COMPOSITION | THE REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1988-01-27 | — | — | EP | disclosed |
| WO-1987004348-A1 | ACYLATED CYANAMIDE COMPOSITION | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117050-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | PAICS, TYMP, OTC | POLB 69/4885SMN1; SMN2 37/4885MEN1 2808/4885 |
| US-20110082115-A1 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen | PAICS, TYMP, OTC | POLB 69/4885SMN1; SMN2 37/4885MEN1 2808/4885 |
| US-20110097426-A1 | Methods for Safe and Effective Treatment Using Oxazaphosphorine Drugs | TYMP, PAICS, ENTPD5 | POLB 174/4885SMN1; SMN2 110/4885MEN1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.